Technology | 2021.04.27
AavantiBio and Catalent Announce Partnership to Support Development and Manufacturing of Gene Therapies for Rare Genetic Diseases
AavantiBio, a gene therapy company focused on transforming the lives of patients with rare genetic diseases, and Catalent, the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products, today announced a partnership to support the development and manufacturing of AavantiBio’s gene therapies, including its lead program in Friedreich’s Ataxia (FA).
(PRWeb April 27, 2021)
Read the full story at https://www.prweb.com/releases/aavantibio_and_catalent_announce_partnership_to_support_development_and_manufacturing_of_gene_therapies_for_rare_genetic_diseases/prweb17895950.htm
For more information, please visit
https://www.prweb.com/releases/aavantibi[...]tic_diseases/prweb17895950.htm
